文献速递产科母胎医学

阴道孕酮与肌内注射17-羟孕酮己酸酯预防复发性早产的比较:一项随机对照试验

Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
PubMed 文献 · Am J Obstet Gynecol · 2022-02-19

该开放标签多中心实用性随机对照试验在5个美国中心纳入既往自发早产的单胎妊娠孕妇,比较阴道孕酮200 mg每晚与肌内注射17-羟孕酮己酸酯250 mg每周预防复发性早产的效果。阴道孕酮组与17-羟孕酮己酸酯组在<37周、<34周和<28周早产率上均无显著差异,但阴道孕酮组平均分娩孕周较晚。

要点

  • 阴道孕酮 vs 肌内注射17-羟孕酮己酸酯:<37周早产率31% vs 38%,无显著差异(P=.28)。
  • 阴道孕酮组平均分娩孕周较17-羟孕酮己酸酯组晚(37.36±2.72 vs 36.34±4.10周,P=.047)。
  • 作者认为阴道孕酮可能延长分娩潜伏期,但该试验检验较小差异的效力不足。

核心结论

  • 与17-羟孕酮己酸酯相比,阴道孕酮未使复发性早产风险降低50%;但阴道孕酮可能延长分娩潜伏期。
  • 该试验检验较小但仍有临床意义的早产预防效果差异的效力不足。
  • 作者建议在孕酮选择的咨询中纳入影响依从性和及时获取药物能力的患者因素。

研究设计与样本

  • 开放标签多中心实用性随机对照试验,在5个美国中心进行。
  • 纳入孕周<24周、既往有自发早产的单胎妊娠孕妇,按1:1随机分配至阴道孕酮200 mg每晚或肌内注射17-羟孕酮己酸酯250 mg每周,用药从孕16周至36周。
  • 基于17-羟孕酮己酸酯组估计复发性早产率36%,每组需95例以检测阴道孕酮使早产率降低50%,把握度80%,双侧α=0.05。
  • 共205例随机化;阴道孕酮组94例和17-羟孕酮己酸酯组94例纳入分析。
  • 主要结局为<37周早产;预设次要结局包括<34周和<28周早产、平均分娩孕周、新生儿发病率和死亡率及依从性指标;采用意向性分析。

主要发现

  • 阴道孕酮组开始治疗孕周早于17-羟孕酮己酸酯组(16.9±1.4 vs 17.8±2.5周;P=.001)。
  • 持续使用分配制剂至分娩的比例两组相似(73% vs 69%;P=.61)。
  • <37周早产率两组无显著差异(31% vs 38%;P=.28;相对风险,0.81[95%置信区间,0.54-1.20])。
  • <34周早产率两组无显著差异(9.6% vs 14.9%;P=.26;相对风险,0.64[95%置信区间,0.29-1.41])。
  • <28周早产率两组无显著差异(1.1% vs 4.3%;P=.37;相对风险,0.25[95%置信区间,0.03-2.20])。

临床怎么用

  • 作者认为阴道孕酮可能延长分娩潜伏期。
  • 作者建议在孕酮选择的咨询中纳入影响依从性和及时获取药物能力的患者因素。

局限性

  • 该试验检验较小但仍有临床意义的早产预防效果差异的效力不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preterm birth is the leading cause of neonatal morbidity and mortality, and previous preterm birth is one of the strongest risk factors for preterm birth. National and international obstetrical societies have different recommendations regarding progesterone formulation for the prevention of recurrent preterm birth. OBJECTIVE: This study aimed to determine whether vaginal progesterone is superior to 17-hydroxyprogesterone caproate in the prevention of recurrent preterm birth in patients with singleton pregnancies who had a previous spontaneous preterm birth. STUDY DESIGN: This was an open-label multicenter pragmatic randomized controlled trial at 5 US centers of patients with singleton pregnancies at <24 weeks of gestation who had a previous spontaneous preterm birth randomized 1:1 to either 200 mg vaginal progesterone suppository nightly or 250 mg intramuscular 17-hydroxyprogesterone caproate weekly from 16 to 36 weeks of gestation. Based on the estimated recurrent preterm birth rate of 36% with 17-hydroxyprogesterone caproate, 95 participants were needed in each arm to detect a 50% reduction in preterm birth rate with vaginal progesterone, with 80% power and 2-sided alpha of 0.05. The primary outcome was preterm birth at <37 weeks of gestation. Prespecified secondary outcomes included preterm birth at <34 and <28 weeks of gestation, mean gestational age at delivery, neonatal morbidity and mortality, and measures of adherence. Analysis was by intention to treat. The chi-square test and Student t test were used as appropriate. P<.05 was considered significant. RESULTS: Overall, 205 participants were randomized; 94 participants in the vaginal progesterone group and 94 participants in 17-hydroxyprogesterone caproate group were included. Although gestational age at enrollment was similar, those assigned to vaginal progesterone initiated therapy earlier (16.9±1.4 vs 17.8±2.5 weeks; P=.001). Overall continuation of assigned formulation until delivery was similar (73% vs 69%; P=.61). There was no significant difference in preterm birth at <37 (31% vs 38%; P=.28; relative risk, 0.81 [95% confidence interval, 0.54-1.20]), <34 (9.6% vs 14.9%; P=.26; relative risk, 0.64 [95% confidence interval, 0.29-1.41]), or <28 (1.1% vs 4.3%; P=.37; relative risk, 0.25 [95% confidence interval, 0.03-2.20]) weeks of gestation. Participants in the vaginal progesterone group had a later mean gestational age at delivery than participants in the 17-hydroxyprogesterone caproate group (37.36±2.72 vs 36.34±4.10 weeks; mean difference, 1.02 [95% confidence interval, 0.01-2.01]; P=.047). CONCLUSION: Vaginal progesterone did not reduce the risk of recurrent preterm birth by 50% compared with 17-OHPC; however, vaginal progesterone may lead to increased latency to delivery. This trial was underpowered to detect a smaller, but still clinically significant, difference in the efficacy of preterm birth prevention. Patient factors that impact adherence and ability to obtain medication in a timely fashion should be included in counseling on progesterone selection.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Boelig RC, Schoen CN, Frey H, et al. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial. Am J Obstet Gynecol. 2022. PMID: 35189093. doi:10.1016/j.ajog.2022.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。